|
1
|
Jeong HM, Kwon MJ and Shin YK:
Overexpression of cancer-associated genes via epigenetic
derepression mechanisms in gynecologic cancer. Front Oncol.
4:122014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhou XM, Zhang H and Han X: Role of
epithelial to mesenchymal transition proteins in gynecological
cancers: Pathological and therapeutic perspectives. Tumour Biol.
35:9523–9530. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu DT: EMMPRIN in gynecologic cancers:
Pathologic and therapeutic aspects. Tumour Biol. 36:4883–4888.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gusberg SB: The gynecologist and breast
cancer. Isr J Med Sci. 17:843–846. 1981.PubMed/NCBI
|
|
5
|
Imani S, Hosseinifard H, Cheng J, Wei C
and Fu J: Prognostic value of EMT-inducing transcription factors
(EMT-TFs) in metastatic breast cancer: A systematic review and
meta-analysis. Sci Rep. 6:285872016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu S, Wang H, Zhang L, Tang C, Jones L,
Ye H, Ban L, Wang A, Liu Z, Lou F, et al: Rapid detection of
genetic mutations in individual breast cancer patients by
next-generation DNA sequencing. Hum Genomics. 9:22015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brody JG, Rudel RA, Michels KB, Moysich
KB, Bernstein L, Attfield KR and Gray S: Environmental pollutants,
diet, physical activity, body size, and breast cancer: Where do we
stand in research to identify opportunities for prevention? Cancer.
109 (12 Suppl):S2627–S2634. 2007. View Article : Google Scholar
|
|
8
|
Rezaeian M, Sharifirad G, Mostafavi F,
Moodi M and Abbasi MH: The effects of breast cancer educational
intervention on knowledge and health beliefs of women 40 years and
older, Isfahan, Iran. J Educ Health Promot. 3:432014.PubMed/NCBI
|
|
9
|
Tania M, Khan MA and Song Y: Association
of lipid metabolism with ovarian cancer. Curr Oncol. 17:6–11. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goff BA: Ovarian cancer: Screening and
early detection. Obstet Gynecol Clin North Am. 39:183–194. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Piek JM, van Diest PJ and Verheijen RH:
Ovarian carcinogenesis: An alternative hypothesis. Adv Exp Med
Biol. 622:79–87. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vargas-Hernández VM, Moreno-Eutimio MA,
Acosta-Altamirano G and Vargas-Aguilar VM: Management of recurrent
epithelial ovarian cancer. Gland Surg. 3:198–202. 2014.PubMed/NCBI
|
|
13
|
Canavan TP and Doshi NR: Cervical cancer.
Am Fam Physician. 61:1369–1376. 2000.PubMed/NCBI
|
|
14
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Muñoz N, Castellsagué X, de González AB
and Gissmann L: Chapter 1: HPV in the etiology of human cancer.
Vaccine. 24 (Suppl 3):S3/1–10. 2006. View Article : Google Scholar
|
|
16
|
Pessoa JN, Freitas AC, Guimaraes RA, Lima
J, Dos Reis HL and Filho AC: Endometrial assessment: When is it
necessary? J Clin Med Res. 6:21–25. 2014.PubMed/NCBI
|
|
17
|
Colombo N, Preti E, Landoni F, Carinelli
S, Colombo A, Marini C and Sessa C; ESMO Guidelines Working Group,
: Endometrial cancer: ESMO clinical practice guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 24 (Suppl
6):vi33–vi38. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lozano R, Naghavi M, Foreman K, Lim S,
Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et
al: Global and regional mortality from 235 causes of death for 20
age groups in 1990 and 2010: A systematic analysis for the global
burden of disease study 2010. Lancet. 380:2095–2128. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dittmer C, Katalinic A, Mundhenke C, Thill
M and Fischer D: Epidemiology of vulvar and vaginal cancer in
Germany. Arch Gynecol Obstet. 284:169–174. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kopp F and Mendell JT: Functional
classification and experimental dissection of long noncoding RNAs.
Cell. 172:393–407. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bassett AR, Akhtar A, Barlow DP, Bird AP,
Brockdorff N, Duboule D, Ephrussi A, Ferguson-Smith AC, Gingeras
TR, Haerty W, et al: Considerations when investigating lncRNA
function in vivo. Elife. 3:e030582014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Soudyab M, Iranpour M and Ghafouri-Fard S:
The role of long non-coding RNAs in breast cancer. Arch Iran Med.
19:508–517. 2016.PubMed/NCBI
|
|
23
|
Geisler S and Coller J: RNA in unexpected
places: Long non-coding RNA functions in diverse cellular contexts.
Nat Rev Mol Cell Biol. 14:699–712. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Grote P and Herrmann BG: Long noncoding
RNAs in organogenesis: Making the difference. Trends Genet.
31:329–335. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nagano T and Fraser P: No-nonsense
functions for long noncoding RNAs. Cell. 145:178–181. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhu Y, Luo M, Brooks M, Clouthier SG and
Wicha MS: Biological and clinical significance of cancer stem cell
plasticity. Clin Transl Med. 3:322014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ørom UA and Shiekhattar R: Long noncoding
RNAs usher in a new era in the biology of enhancers. Cell.
154:1190–1193. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wahlestedt C: Targeting long non-coding
RNA to therapeutically upregulate gene expression. Nat Rev Drug
Discov. 12:433–446. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang X, Hamblin MH and Yin KJ: The long
noncoding RNA Malat1: Its physiological and pathophysiological
functions. RNA Biol. 14:1705–1714. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hutchinson JN, Ensminger AW, Clemson CM,
Lynch CR, Lawrence JB and Chess A: A screen for nuclear transcripts
identifies two linked noncoding RNAs associated with SC35 splicing
domains. BMC Genomics. 8:392007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang B, Arun G, Mao YS, Lazar Z, Hung G,
Bhattacharjee G, Xiao X, Booth CJ, Wu J, Zhang C and Spector DL:
The lncRNA Malat1 is dispensable for mouse development but its
transcription plays a cis-regulatory role in the adult. Cell Rep.
2:111–123. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bernard D, Prasanth KV, Tripathi V,
Colasse S, Nakamura T, Xuan Z, Zhang MQ, Sedel F, Jourdren L,
Coulpier F, et al: A long nuclear-retained non-coding RNA regulates
synaptogenesis by modulating gene expression. EMBO J. 29:3082–3093.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wilusz JE, Freier SM and Spector DL: 3′
end processing of a long nuclear-retained noncoding RNA yields a
tRNA-like cytoplasmic RNA. Cell. 135:919–932. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tano K, Mizuno R, Okada T, Rakwal R,
Shibato J, Masuo Y, Ijiri K and Akimitsu N: MALAT-1 enhances cell
motility of lung adenocarcinoma cells by influencing the expression
of motility-related genes. FEBS Lett. 584:4575–4580. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang L, Lin C, Liu W, Zhang J, Ohgi KA,
Grinstein JD, Dorrestein PC and Rosenfeld MG: ncRNA- and Pc2
methylation-dependent gene relocation between nuclear structures
mediates gene activation programs. Cell. 147:773–788. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ji P, Diederichs S, Wang W, Böing S,
Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, et
al: MALAT-1, a novel noncoding RNA, and thymosin beta4 predict
metastasis and survival in early-stage non-small cell lung cancer.
Oncogene. 22:8031–8041. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gutschner T, Hämmerle M, Eissmann M, Hsu
J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al:
The noncoding RNA MALAT1 is a critical regulator of the metastasis
phenotype of lung cancer cells. Cancer Res. 73:1180–1189. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shi X, Sun M, Wu Y, Yao Y, Liu H, Wu G,
Yuan D and Song Y: Post-transcriptional regulation of long
noncoding RNAs in cancer. Tumour Biol. 36:503–513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li Z, Xu L, Liu Y, Fu S, Tu J, Hu Y and
Xiong Q: LncRNA MALAT1 promotes relapse of breast cancer patients
with postoperative fever. Am J Transl Res. 10:3186–3197.
2018.PubMed/NCBI
|
|
40
|
Zhao M, Wang S, Li Q, Ji Q, Guo P and Liu
X: MALAT1: A long non-coding RNA highly associated with human
cancers. Oncol Lett. 16:19–26. 2018.PubMed/NCBI
|
|
41
|
Tee AE, Ling D, Nelson C, Atmadibrata B,
Dinger ME, Xu N, Mizukami T, Liu PY, Liu B, Cheung B, et al: The
histone demethylase JMJD1A induces cell migration and invasion by
up-regulating the expression of the long noncoding RNA MALAT1.
Oncotarget. 5:1793–1804. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Peng R, Luo C, Guo Q, Cao J, Yang Q, Dong
K, Wang S, Wang K and Song C: Association analyses of genetic
variants in long non-coding RNA MALAT1 with breast cancer
susceptibility and mRNA expression of MALAT1 in Chinese Han
population. Gene. 642:241–248. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen Q, Zhu C and Jin Y: The oncogenic and
tumor suppressive functions of the long noncoding RNA MALAT1: An
emerging controversy. Front Genet. 11:932020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ni W, Wang X, Sun Y and Gao X:
Meta-analysis of the association between MALAT1 rs619586 A>G
polymorphism and cancer risk. J Int Med Res.
48:3000605209419692020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang P, Zhou H, Lu K, Lu Y, Wang Y and
Feng T: Exosome-mediated delivery of MALAT1 induces cell
proliferation in breast cancer. Onco Targets Ther. 11:291–299.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang Y, Zhang Y, Hu K, Qiu J, Hu Y, Zhou M
and Zhang S: Elevated long noncoding RNA MALAT-1 expression is
predictive of poor prognosis in patients with breast cancer: A
meta-analysis. Biosci Rep. 40:BSR202002152020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Stone JK, Kim JH, Vukadin L, Richard A,
Giannini HK, Lim SS, Tan M and Ahn EE: Hypoxia induces cancer
cell-specific chromatin interactions and increases MALAT1
expression in breast cancer cells. J Biol Chem. 294:11213–11224.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zheng L, Zhang Y, Fu Y, Gong H, Guo J, Wu
K, Jia Q and Ding X: Long non-coding RNA MALAT1 regulates BLCAP
mRNA expression through binding to miR-339-5p and promotes poor
prognosis in breast cancer. Biosci Rep. 39:BSR201812842019.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fattahi Dolatabadi N, Dehghani A, Shahand
E, Yazdanshenas M, Tabatabaeian H, Zamani A, Azadeh M and Ghaedi K:
The interaction between MALAT1 target, miR-143-3p, and RALGAPA2 is
affected by functional SNP rs3827693 in breast cancer. Hum Cell.
33:1229–1239. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Gomes CP, Nóbrega-Pereira S,
Domingues-Silva B, Rebelo K, Alves-Vale C, Marinho SP, Carvalho T,
Dias S and Bernardes de Jesus B: An antisense transcript mediates
MALAT1 response in human breast cancer. BMC Cancer. 19:7712019.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wu Y, Sarkissyan M, Ogah O, Kim J and
Vadgama JV: Expression of MALAT1 promotes trastuzumab resistance in
HER2 overexpressing breast cancers. Cancers (Basel). 12:19182020.
View Article : Google Scholar
|
|
52
|
Huang XJ, Xia Y, He GF, Zheng LL, Cai YP,
Yin Y and Wu Q: MALAT1 promotes angiogenesis of breast cancer.
Oncol Rep. 40:2683–2689. 2018.PubMed/NCBI
|
|
53
|
Kim J, Piao HL, Kim BJ, Yao F, Han Z, Wang
Y, Xiao Z, Siverly AN, Lawhon SE, Ton BN, et al: Long noncoding RNA
MALAT1 suppresses breast cancer metastasis. Nat Genet.
50:1705–1715. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kwok ZH, Roche V, Chew XH, Fadieieva A and
Tay Y: A non-canonical tumor suppressive role for the long
non-coding RNA MALAT1 in colon and breast cancers. Int J Cancer.
143:668–678. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Eastlack SC, Dong S, Mo YY and Alahari SK:
Expression of long noncoding RNA MALAT1 correlates with increased
levels of Nischarin and inhibits oncogenic cell functions in breast
cancer. PLoS One. 13:e01989452018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Arun G and Spector DL: MALAT1 long
non-coding RNA and breast cancer. RNA Biol. 16:860–863. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Liu SP, Yang JX, Cao DY and Shen K:
Identification of differentially expressed long non-coding RNAs in
human ovarian cancer cells with different metastatic potentials.
Cancer Biol Med. 10:138–141. 2013.PubMed/NCBI
|
|
58
|
Hosseini ES, Meryet-Figuiere M,
Sabzalipoor H, Kashani HH, Nikzad H and Asemi Z: Dysregulated
expression of long noncoding RNAs in gynecologic cancers. Mol
Cancer. 16:1072017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Sun Q, Li Q and Xie F: LncRNA-MALAT1
regulates proliferation and apoptosis of ovarian cancer cells by
targeting miR-503-5p. Onco Targets Ther. 12:6297–6307. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Khan MA, Chen HC, Zhang D and Fu J: Twist:
A molecular target in cancer therapeutics. Tumour Biol.
34:2497–2506. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Tania M, Khan MA and Fu J: Epithelial to
mesenchymal transition inducing transcription factors and
metastatic cancer. Tumour Biol. 35:7335–7342. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Jin Y, Feng SJ, Qiu S, Shao N and Zheng
JH: LncRNA MALAT1 promotes proliferation and metastasis in
epithelial ovarian cancer via the PI3K-AKT pathway. Eur Rev Med
Pharmacol Sci. 21:3176–3184. 2017.PubMed/NCBI
|
|
63
|
Guo C and Wang X, Chen LP, Li M, Li M, Hu
YH, Ding WH and Wang X: Long non-coding RNA MALAT1 regulates
ovarian cancer cell proliferation, migration and apoptosis through
Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci.
22:3703–3712. 2018.PubMed/NCBI
|
|
64
|
Wang ZM, Wan XH, Sang GY, Zhao JD, Zhu QY
and Wang DM: miR-15a-5p suppresses endometrial cancer cell growth
via Wnt/β-catenin signaling pathway by inhibiting WNT3A. Eur Rev
Med Pharmacol Sci. 21:4810–4818. 2017.PubMed/NCBI
|
|
65
|
Qiu JJ, Lin XJ, Tang XY, Zheng TT, Lin YY
and Hua KQ: Exosomal metastasis-associated lung adenocarcinoma
transcript 1 promotes angiogenesis and predicts poor prognosis in
epithelial ovarian cancer. Int J Biol Sci. 14:1960–1973. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhou Y, Xu X, Lv H, Wen Q, Li J, Tan L, Li
J and Sheng X: The long noncoding RNA MALAT-1 is highly expressed
in ovarian cancer and induces cell growth and migration. PLoS One.
11:e01552502016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Yang L, Bai HS, Deng Y and Fan L: High
MALAT1 expression predicts a poor prognosis of cervical cancer and
promotes cancer cell growth and invasion. Eur Rev Med Pharmacol
Sci. 19:3187–3193. 2015.PubMed/NCBI
|
|
68
|
Jiang Y, Li Y, Fang S, Jiang B, Qin C, Xie
P, Zhou G and Li G: The role of MALAT1 correlates with HPV in
cervical cancer. Oncol Lett. 7:2135–2141. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Lu H, He Y, Lin L, Qi Z, Ma L, Li L and Su
Y: Long non-coding RNA MALAT1 modulates radiosensitivity of HR-HPV+
cervical cancer via sponging miR-145. Tumour Biol. 37:1683–1691.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Han X, Wang Q, Wang Y, Hu B, Dong X, Zhang
H and Wang W: Long non-coding RNA metastasis-associated lung
adenocarcinoma transcript 1/microRNA-202-3p/periostin axis
modulates invasion and epithelial-mesenchymal transition in human
cervical cancer. J Cell Physiol. 234:14170–14180. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Wang N, Hou MS, Zhan Y, Shen XB and Xue
HY: MALAT1 promotes cisplatin resistance in cervical cancer by
activating the PI3K/AKT pathway. Eur Rev Med Pharmacol Sci.
22:7653–7659. 2018.PubMed/NCBI
|
|
72
|
Zhao Y, Yang Y, Trovik J, Sun K, Zhou L,
Jiang P, Lau TS, Hoivik EA, Salvesen HB, Sun H and Wang H: A novel
wnt regulatory axis in endometrioid endometrial cancer. Cancer Res.
74:5103–5117. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Chen G, Zhang M, Liang Z, Chen S, Chen F,
Zhu J, Zhao M, He J, Hua W and Duan P: Association of polymorphisms
in MALAT1 with the risk of endometrial cancer in Southern Chinese
women. J Clin Lab Anal. 34:e231462020.PubMed/NCBI
|
|
74
|
Cao X, Zhao R, Chen Q, Zhao Y, Zhang B,
Zhang Y, Yu J, Han G, Cao W, Li J and Chen X: MALAT1 might be a
predictive marker of poor prognosis in patients who underwent
radical resection of middle thoracic esophageal squamous cell
carcinoma. Cancer Biomark. 15:717–723. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Liu R, Li J, Lai Y, Liao Y, Liu R and Qiu
W: Hsa-miR-1 suppresses breast cancer development by
down-regulating K-ras and long non-coding RNA MALAT1. Int J Biol
Macromol. 81:491–497. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Arun G, Diermeier S, Akerman M, Chang KC,
Wilkinson JE, Hearn S, Kim Y, MacLeod AR, Krainer AR, Norton L, et
al: Differentiation of mammary tumors and reduction in metastasis
upon Malat1 lncRNA loss. Genes Dev. 30:34–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Gordon MA, Babbs B, Cochrane DR, Bitler BG
and Richer JK: The long non-coding RNA MALAT1 promotes ovarian
cancer progression by regulating RBFOX2-mediated alternative
splicing. Mol Carcinog. 58:196–205. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Bai L, Wang A, Zhang Y, Xu X and Zhang X:
Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer
cells to cisplatin through inhibiting the Notch1 signaling pathway.
Exp Cell Res. 366:161–171. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Worku T, Bhattarai D, Ayers D, Wang K,
Wang C, Rehman ZU, Talpur HS and Yang L: Long non-coding RNAs: The
new horizon of gene regulation in ovarian cancer. Cell Physiol
Biochem. 44:948–966. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Pa M, Naizaer G, Seyiti A and Kuerbang G:
Long noncoding RNA MALAT1 functions as a sponge of MiR-200c in
ovarian cancer. Oncol Res. Sep 11–2017.(Epub ahead of print).
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Lei R, Xue M, Zhang L and Lin Z: Long
noncoding RNA MALAT1-regulated microRNA 506 modulates ovarian
cancer growth by targeting iASPP. Onco Targets Ther. 10:35–46.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Zhu P, Wang FQ and Li QR: Correlation
study between long non-coding RNA MALAT1 and radiotherapy
efficiency on cervical carcinoma and generation of radiotherapy
resistant model of cancer. Eur Rev Med Pharmacol Sci. 22:5140–5148.
2018.PubMed/NCBI
|
|
83
|
Sun R, Qin C, Jiang B, Fang S, Pan X, Peng
L, Liu Z, Li W, Li Y and Li G: Down-regulation of MALAT1 inhibits
cervical cancer cell invasion and metastasis by inhibition of
epithelial-mesenchymal transition. Mol Biosyst. 12:952–962. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Xia C, Liang S, He Z, Zhu X, Chen R and
Chen J: Metformin, a first-line drug for type 2 diabetes mellitus,
disrupts the MALAT1/miR-142-3p sponge to decrease invasion and
migration in cervical cancer cells. Eur J Pharmacol. 830:59–67.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Li Q, Zhang C, Chen R, Xiong H, Qiu F, Liu
S, Zhang M, Wang F, Wang Y, Zhou X, et al: Disrupting
MALAT1/miR-200c sponge decreases invasion and migration in
endometrioid endometrial carcinoma. Cancer Lett. 383:28–40. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Tian X and Xu G: Clinical value of lncRNA
MALAT1 as a prognostic marker in human cancer: Systematic review
and meta-analysis. BMJ Open. 5:e0086532015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Du Z, Fei T, Verhaak RG, Su Z, Zhang Y,
Brown M, Chen Y and Liu XS: Integrative genomic analyses reveal
clinically relevant long noncoding RNAs in human cancer. Nat Struct
Mol Biol. 20:908–913. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Liao H, Chen Q and Xiao J: Reflections on
the role of Malat1 in gynecological cancer. Cancer Manag Res.
12:13489–13500. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Sun Y and Ma L: New insights into long
non-coding RNA MALAT1 in cancer and metastasis. Cancers (Basel).
11:2162019. View Article : Google Scholar
|
|
90
|
Amodio N, Raimondi L, Juli G, Stamato MA,
Caracciolo D, Tagliaferri P and Tassone P: MALAT1: A druggable long
non-coding RNA for targeted anti-cancer approaches. J Hematol
Oncol. 11:632018. View Article : Google Scholar : PubMed/NCBI
|
